AUTH/2443/10/11: Anonymous v Genus Pharmaceuticals — conduct of Apo-go nurse advisor (No breach)

No breach of the Code was found in relation to concerns raised about an Apo-go (apomorphine hydrochloride) nurse advisor employed by Genus Pharmaceuticals Ltd.

What happened

• An anonymous, uncontactable complainant (describing themself as a “concerned pharmacist”) complained about the conduct of a local Apo-go nurse advisor supporting Parkinson’s disease patients.
• The complainant alleged the nurse advisor (not a nurse prescriber) was changing oral Parkinson’s disease medicines and increasing apomorphine doses, and was not informing local Parkinson’s Disease Nurse Specialists (PDNSs) about changes or patient responses.
• The complainant alleged this posed a significant patient safety risk and that clinicians did not know why changes had been made.
• Genus responded that the nurse support programme was a patient support package linked to Apo-go therapy, operated independently of the commercial team, and worked under programme agreements, trust honorary contracts, and patient consent.
• Genus submitted anonymised patient notes and a consultant neurologist testimonial stating the nurse advisor consulted the consultant “without exception” whenever prescription alterations were required.

Outcome

• The Panel noted the burden of proof lay with the complainant on the balance of probabilities; anonymous complaints are accepted but must be evidenced.
• The Panel considered the nurse support programme was linked to Apo-go and therefore, in effect, a package deal under the supplementary information to Clause 18.1.
• The Panel found the arrangements constituted a bona fide package deal and did not amount to an improper inducement.
• The Panel found the service could not be considered a medical/educational good or service under Clause 18.4 because it bore the name “Apo-go” and was inextricably linked to the product; however, it was not covered by Clause 18.4 due to being treated as a package deal, so no breach was found.
• Based on the evidence (including patient notes and consultant testimony) and lack of supporting evidence from the complainant, the Panel found the nurse advisor had not failed to maintain high standards and the matter did not bring discredit to the industry.

Clauses considered

• Clause 2
• Clause 9.1
• Clause 18.1
• Clause 18.4

Sanctions

• None (No breach of the Code).

Why this matters

• Patient support programmes that are tightly linked to a medicine can be scrutinised as potential inducements; you need to be able to evidence that the overall arrangement is fair, reasonable, and relevant to the medicine involved.
• Where company-employed nurses interact with patients and clinical teams, role clarity, governance, documentation, and prescriber control are critical—especially where medication changes are discussed or implemented.
• Anonymous complaints can still proceed; the best defence is contemporaneous documentation and clear contractual frameworks (programme agreement, honorary contract, patient consent, and communication records).

Where teams slip up

• Calling a programme “non-promotional” without defining what that means in practice (the Panel noted it was unsure what was meant by “non-promotional”).
• Blurring boundaries between “supporting” a prescriber’s decision and independently initiating/implementing medication changes.
• Insufficient written evidence of prescriber instruction, escalation, and communication back to the wider care team (eg PDNS/GP).
• Branding a service with the medicine name and then trying to position it as a “medical and educational good or service” rather than addressing it under package deal principles.

Control that would have prevented it

• A formal governance pack for nurse support programmes: signed programme agreement, trust honorary contract, and patient consent before any interaction.
• Clear SOPs stating: prescriber retains clinical responsibility; nurse advisor acts only on explicit prescriber instruction (with defined emergency exceptions) and documents all actions.
• Mandatory communication protocol: every medication-related change/action recorded and promptly shared with the responsible consultant/PDNS/GP as appropriate.
• Periodic audits of nurse notes and correspondence to confirm prescriber instruction and documentation standards.